Facts, fakes and "biblio". Do internists still have something to learn about dexfenfluramine?;Faits, mensonges et « biblio » les internistes ont-ils encore des choses à apprendre sur la dexfenfluramine?

Annales de Medecine Interne

Volumn 152, Issue 7, 2001, Pages 427-428

  Bergmann, Jean François ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEXFENFLURAMINE; SEROTONIN ANTAGONIST;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; HUMAN; HYPERTENSION; VALVULAR HEART DISEASE; CHEMICALLY INDUCED DISORDER; OBESITY; PULMONARY HYPERTENSION;

DEXFENFLURAMINE; HEART VALVE DISEASES; HUMANS; HYPERTENSION, PULMONARY; OBESITY; SEROTONIN ANTAGONISTS;

EID: 0035699427     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (10)

1. Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: Facts and artifacts
2. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study group
3. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs
4. A population-based study of appetite-suppressants drugs and the risk of cardiac valve regurgitation
5. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine and phentermine/fenfluramine
6. Fenfluramine and phentermine and cardiovascular findings. Effect of treatment duration on prevalence of valve abnormalities
7. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained release dexfenfluramine study group
8. Principes des essais thérapeutiques
9. Obesity